BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

Seiji Nagashima; Hiroshi Soda; Mikio Oka; Takeshi Kitazaki; Ken Shiozawa; Yoichi Nakamura; Masaaki Takemura; Hikaru Yabuuchi; Minoru Fukuda; Kazuhiro Tsukamoto

doi:10.1007/s00280-006-0212-y

BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

Identifier:nobleid.org/w1/20260515/6BC2F736

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/6BC2F736.svg?ark=w1%2F20260515%2F6BC2F736)](https://nobleid.org/work/w1/20260515/6BC2F736)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

Identifier:nobleid.org/w1/20260515/6BC2F736

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/6BC2F736.svg?ark=w1%2F20260515%2F6BC2F736)](https://nobleid.org/work/w1/20260515/6BC2F736)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work